TrivarX

TrivarX Gross Margin

The Gross Margin of TrivarX (TRI.AX) as of Oct 27, 2026 is -4.65 %. In the previous year, Gross Margin was -10.43 % — a change of -55.42% (higher).

Gross Margin

-4.65 %

YoY

-55.42%

Last updated:

Gross Margin of TrivarX is 2025 -4.65 % . Gross Margin of TrivarX was 2024 -10.43 % . It decreases by -55.42% higher compared to the previous year.

For TrivarX, the gross margin of -4.6% is up versus -67.9% a few years ago.

The TrivarX Gross Margin history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Gross Margin
Date
Gross Margin
Jan 1, 2018
63.07 AUD
Jan 1, 2019
37.99 AUD
Jan 1, 2020
-53.32 AUD
Jan 1, 2021
-67.92 AUD
Jan 1, 2022
97.33 AUD
Jan 1, 2023
99.28 AUD
Jan 1, 2024
-10.43 AUD
Jan 1, 2025
-4.65 AUD
The TrivarX Gross Margin history
YEARGross MarginYoY
-4.65 %-55.42%
-10.43 %-110.50%
99.28 %+2.01%
97.33 %-243.30%
-67.92 %+27.37%
-53.32 %-240.35%
37.99 %-39.76%
63.07 %-36.93%
100.00 %0.00%
100.00 %+2.67%
97.40 %-1,142.67%
-9.34 %+25.42%
-7.45 %-4,001.20%
0.19 %-55.31%
0.43 %-57.28%
1.00 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

TrivarX Stock analysis

What does TrivarX do? TrivarX Ltd generates revenue through its corporate health product, which provides mental well-being solutions for businesses. The company develops and commercializes mental health technology using objective biomarkers for screening, diagnosing, monitoring, and managing depression. Its consumer mobile application LUCA offers biometric assessments measuring sleep stress, activity stress, and cardiac stress, enabling users to monitor stress levels via personal wearable devices. The company focuses on early detection and screening of mental health conditions through clinical research and product development. The primary buyers of TrivarX's corporate health product are businesses seeking mental well-being solutions for their employees. The consumer application LUCA targets individuals interested in monitoring their stress levels using wearable technology. TrivarX's technology is designed to assist in the early detection and screening of mental health conditions, with a focus on depression management through objective biomarker analysis. The company's clinical research and product development activities support both business and consumer segments in the mental health technology market. TrivarX is one of the most popular companies on Eulerpool.

Frequently Asked Questions about TrivarX stock

Gross Margin of TrivarX is -4.65 % in 2025.

Gross Margin of TrivarX changed from -10.43 % to -4.65 %, representing a -55.42% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Gross Margin TrivarX since 2006 – with annual values, charts, and detailed analysis.

Gross Margin measures the percentage of revenue remaining after COGS. Higher gross margins indicate more efficient production and stronger pricing power.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Gross Margin's TrivarX with sector peers and the industry average to assess whether it is attractive.

To evaluate Gross Margin's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Gross Margin.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Margins — TrivarX

All Key Metrics — TrivarX